Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,shortLongTermDebt,longTermDebt,deferredLongTermLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,changeToInventory,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,priceHint,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HSTO,24931000.0,35744500,,,-3720000,-971000,-3704000,1822000,-2371000,-4193000,-4193000,,-2000,,,,0,5000,4198000,2376000,473000,,-3720000,-3704000,95603000.0,6841000.0,24931000.0,336000.0,30801000.0,4000.0,193000.0,-70676000.0,108000.0,1109000.0,23140000.0,2128000.0,4561000.0,25131000.0,118000.0,61000.0,586000.0,,,,85000.0,-45000.0,-2000.0,5757000.0,-596000.0,5759000.0,1397000.0,-4315000.0,23000.0,70000.0,-193000.0,-45000.0,,,23003000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,0.8202,1630526402,0.029900014,0.818,0.835,0.8038,455508,Histogen Inc.,NCM,PRE,-0.21441141,0,False,False,3.783375,0.8038 - 0.835,0.7903,0.0,0.0,9,29,finmb_44460054,NasdaqCM,Histogen Inc.,USD,1854050,264657,0.08020002,0.1083784,0.74 - 2.41,-1.5898001,-0.6596681,0.74,2.41,1590537600,1615496400,1615496400,1615496400,4,-0.46,-1.7830435,0.83,-0.009799957,-0.011807177,1.044058,-0.22385794,29317640,15,America/New_York,EDT,-14400000,,,,2.41,0.74,0.83,1.0441,1.85M,264.66k,35.74M,,36.34M,7.03%,6.42%,420.78k,0.35,1.08%,1.01%,393.22k,,,,,,0.00%,"May 26, 2020",,1:10,"May 26, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,087.30%",-39.42%,-90.80%,1.41M,0.06,-95.40%,-5.02M,-15.23M,-14.73M,,,23.14M,0.56,4.61M,19.25,11.81,,-15.75M,-11.13M,Value,92121,Healthcare,19,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",San Diego,858 526 3100,CA,1609372800,United States,http://www.histogen.com,86400,10655 Sorrento Valley Road,Biotechnology,Suite 200
t-1,HSTO,22586000.0,35744500,,,-4278000,-955000,-4270000,2331000,-1942000,-4273000,-4273000,,-5000,,,,0,431000,4704000,2373000,-5000,,-4278000,-4270000,89554000.0,7182000.0,22586000.0,309000.0,28813000.0,4000.0,150000.0,-66972000.0,113000.0,1166000.0,21743000.0,1976000.0,4739000.0,22908000.0,188000.0,61000.0,496000.0,156000.0,310000.0,,-77000.0,-45000.0,-2000.0,18592000.0,316000.0,18787000.0,14980000.0,-3612000.0,23000.0,-44000.0,201000.0,-45000.0,239000.0,-193000.0,20932000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,0.8202,1630526402,0.029900014,0.818,0.835,0.8038,455508,Histogen Inc.,NCM,PRE,-0.21441141,0,False,False,3.783375,0.8038 - 0.835,0.7903,0.0,0.0,9,29,finmb_44460054,NasdaqCM,Histogen Inc.,USD,1854050,264657,0.08020002,0.1083784,0.74 - 2.41,-1.5898001,-0.6596681,0.74,2.41,1590537600,1615496400,1615496400,1615496400,4,-0.46,-1.7830435,0.83,-0.009799957,-0.011807177,1.044058,-0.22385794,29317640,15,America/New_York,EDT,-14400000,,,,2.41,0.74,0.83,1.0441,1.85M,264.66k,35.74M,,36.34M,7.03%,6.42%,420.78k,0.35,1.08%,1.01%,393.22k,,,,,,0.00%,"May 26, 2020",,1:10,"May 26, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,087.30%",-39.42%,-90.80%,1.41M,0.06,-95.40%,-5.02M,-15.23M,-14.73M,,,23.14M,0.56,4.61M,19.25,11.81,,-15.75M,-11.13M,Value,92121,Healthcare,19,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",San Diego,858 526 3100,CA,1609372800,United States,http://www.histogen.com,86400,10655 Sorrento Valley Road,Biotechnology,Suite 200
t-2,HSTO,7860000.0,35744500,,,-3522000,-947000,-3508000,1939000,-1569000,-3508000,-3508000,,-11000,,,,0,478000,3986000,2047000,-14000,,-3522000,-3508000,70561000.0,8100000.0,7860000.0,940000.0,15013000.0,1000.0,406000.0,-62702000.0,118000.0,1931000.0,6763000.0,2785000.0,4682000.0,8400000.0,144000.0,300000.0,539000.0,97000.0,369000.0,708000.0,-744000.0,-6000.0,-3000.0,3944000.0,-174000.0,3761000.0,-136000.0,-4074000.0,24000.0,27000.0,164000.0,-45000.0,137000.0,186000.0,5615000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,0.8202,1630526402,0.029900014,0.818,0.835,0.8038,455508,Histogen Inc.,NCM,PRE,-0.21441141,0,False,False,3.783375,0.8038 - 0.835,0.7903,0.0,0.0,9,29,finmb_44460054,NasdaqCM,Histogen Inc.,USD,1854050,264657,0.08020002,0.1083784,0.74 - 2.41,-1.5898001,-0.6596681,0.74,2.41,1590537600,1615496400,1615496400,1615496400,4,-0.46,-1.7830435,0.83,-0.009799957,-0.011807177,1.044058,-0.22385794,29317640,15,America/New_York,EDT,-14400000,,,,2.41,0.74,0.83,1.0441,1.85M,264.66k,35.74M,,36.34M,7.03%,6.42%,420.78k,0.35,1.08%,1.01%,393.22k,,,,,,0.00%,"May 26, 2020",,1:10,"May 26, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,087.30%",-39.42%,-90.80%,1.41M,0.06,-95.40%,-5.02M,-15.23M,-14.73M,,,23.14M,0.56,4.61M,19.25,11.81,,-15.75M,-11.13M,Value,92121,Healthcare,19,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",San Diego,858 526 3100,CA,1609372800,United States,http://www.histogen.com,86400,10655 Sorrento Valley Road,Biotechnology,Suite 200
t-3,HSTO,7445000.0,35744500,,,-3263000,-933000,-3249000,1982000,-1364000,-3346000,-3346000,,-25000,,,,0,495000,3841000,1859000,83000,,-3263000,-3249000,66638000.0,7150000.0,7445000.0,103000.0,13952000.0,1000.0,243000.0,-59194000.0,123000.0,1341000.0,6649000.0,1825000.0,4629000.0,7982000.0,171000.0,453000.0,1130000.0,39000.0,428000.0,,-263000.0,-1330000.0,-2000.0,1335000.0,-315000.0,1337000.0,-3745000.0,-3750000.0,23000.0,-35000.0,136000.0,-45000.0,-47000.0,186000.0,6157000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,0.8202,1630526402,0.029900014,0.818,0.835,0.8038,455508,Histogen Inc.,NCM,PRE,-0.21441141,0,False,False,3.783375,0.8038 - 0.835,0.7903,0.0,0.0,9,29,finmb_44460054,NasdaqCM,Histogen Inc.,USD,1854050,264657,0.08020002,0.1083784,0.74 - 2.41,-1.5898001,-0.6596681,0.74,2.41,1590537600,1615496400,1615496400,1615496400,4,-0.46,-1.7830435,0.83,-0.009799957,-0.011807177,1.044058,-0.22385794,29317640,15,America/New_York,EDT,-14400000,,,,2.41,0.74,0.83,1.0441,1.85M,264.66k,35.74M,,36.34M,7.03%,6.42%,420.78k,0.35,1.08%,1.01%,393.22k,,,,,,0.00%,"May 26, 2020",,1:10,"May 26, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,087.30%",-39.42%,-90.80%,1.41M,0.06,-95.40%,-5.02M,-15.23M,-14.73M,,,23.14M,0.56,4.61M,19.25,11.81,,-15.75M,-11.13M,Value,92121,Healthcare,19,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",San Diego,858 526 3100,CA,1609372800,United States,http://www.histogen.com,86400,10655 Sorrento Valley Road,Biotechnology,Suite 200
